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Hip fracture cohort  
(9,034 non-BP users; 4,940 BP-users) 
 
Aged <50 (304, 3.4% non-BP users; 48, 1.0% BP-users) 
 
AMD before index date  
(537, 5.9% non-BP users; 279, 5.6% BP-users) 
BP before index date 
(794, 8.8% non-BP users; 1,315, 26.6% BP-users) 
 
Index date <1y prior to censoring date 
(366, 4.1% non-BP users; 184, 3.7% BP-users) 
 
Dead, transferred out, last data prior to index date  
(171, 3.5% non-BP users) 
 
Absence of a matched BP-user or non-BP user 
(3,730, 41.3% non-BP users; 1, 0.02% BP-users) 
 
AMD during 1st year of follow-up 
(28, 0.3% non-BP users; 9, 0.2% BP-users) 
 
Hip fracture matched cohort  
(3,104, 34.4% non-BP users; 3,104, 62.8% BP-users) 
152 AMD cases 
 
6,208 patients for the 
Competing risk analysis 
 
Absence of a matched AMD-case or control 
53 AMD cases; 4073 controls 
 
AMD nested case-control 1:20  
99 AMD cases matched to 1,980 controls 
 
2,079 patients for the 
nested case-control 
analysis 
 
